Htoo, Phyo T.
Tesfaye, Helen
Schneeweiss, Sebastian
Wexler, Deborah J.
Everett, Brendan M.
Glynn, Robert J.
Schmedt, Niklas
Koeneman, Lisette
Déruaz-Luyet, Anouk
Paik, Julie M.
Patorno, Elisabetta
Funding for this research was provided by:
Boehringer Ingelheim (116283)
Article History
Received: 16 October 2023
Accepted: 30 January 2024
First Online: 8 February 2024
Change Date: 18 March 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12933-024-02190-6
Declarations
:
: The institutional review board at the Brigham and Women’s Hospital approved the protocol. Data use agreements with the data vendors were in place. Informed consent was waived since the databases used were secondary administrative healthcare databases.
: All authors have provided the consent for publication.
: PTH previously worked at Johnson & Johnson on an unrelated work. HT has nothing to disclose. SS reports investigator-initiated grants to the Brigham and Women’s Hospital from Boehringer Ingelheim and owns equity in a software manufacturer, Aetion, Inc. DJW reports serving on data monitoring committees for Novo Nordisk and consulting for Elsevier and UpToDate, and grants from PCORI. BME reports consulting for, Janssen, Eli Lilly and Company, Provention Bio, Ipsen Pharmaceuticals, Novo Nordisk, NIDDK, American Heart Association, and UptoDate and grants from PCORI and Novo Nordisk outside the submitted work. RJG reports grants from Amgen, AstraZeneca, Kowa, Novartis, Pfizer outside the submitted work. LK is an employee of Eli Lilly and Company and owns stock in Eli Lilly and Company. NS and ADL are employees of Boehringer Ingelheim International GmbH. None for JMP. Dr. Patorno reported receiving grants from Boehringer Ingelheim during the conduct of the study and grants from the Food and Drug Administration and the Patient-Centered Outcomes Research Institute outside the submitted work. The authors did not receive any payment related to the development of the manuscript. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations.